Company: WHWK
Filing Date: 2025-02-19
Form Type: DEFA14A
Source: 0001193125-25-029692
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-02-19
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material under §240.14a-12 |

AADI BIOSCIENCE, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11.                                                          |

Dear Fellow Aadi Stockholders, I am writing to encourage you to use the enclosed proxy card to vote in favor of the proposals that are being put to a vote at Aadi Bioscience’s upcoming Special Meeting of Stockholders, which is scheduled to be held on February 28, 2025. The proposals on the ballot at this meeting are critical to Aadi’s future. Please vote online at your earliest convenience to ensure your voice is heard. Aadi is on the cusp of an exciting transformation, which can only be achieved if stockholders approve the proposals on the ballot at the Special Meeting. After a thorough process and substantial deliberation, the Board concluded the best path forward for Aadi involves:

| • |     | The sale of FYARRO® and its associated                            
 infrastructure to Kaken Pharmaceuticals for $100 million in cash; |

| • |     | The in-licensing of a thoughtfully selected, promising portfolio                         
 of cancer treatments known as antibody drug conjugates (“ADCs”) from WuXi Biologics; and |

| • |     | A $100 million private investment in public equity (“PIPE”) financing to enable the 
 development of these new assets.                                                    |

Upon closing these three strategic transactions, we believe Aadi will be well positioned to develop next